Outlook Therapeutics
OTLK
30 hedge funds and large institutions have $7.76M invested in Outlook Therapeutics in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.
178% more capital invested
Capital invested by funds: $2.79M → $7.76M (+$4.97M)
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
11% more funds holding
Funds holding: 27 → 30 (+3)
0.08% more ownership
Funds ownership: 0.15% → 0.23% (+0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.73M |
| 2 |
Millennium Management
New York
|
+$189K |
| 3 |
VF
Virtu Financial
New York
|
+$94.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$91.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$65.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$54.4K |
| 2 |
Goldman Sachs
New York
|
-$32.9K |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$24.3K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$22K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $12K | +$1.59K | +76 | +20% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $9K | +$7.06K | +338 | New |
|
|
CFGS
28
Concourse Financial Group Securities
Birmingham,
Alabama
| $2K | – | – | – |
|
|
PWMG
29
Prestige Wealth Management Group
Flemington,
New Jersey
| $2K | – | – | – |
|
|
RJFSA
30
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$22K | -1,500 | Closed |
|
31
LPL Financial
San Diego,
California
| – | -$15K | -1,009 | Closed |
|
|
WG
32
Winton Group
London,
United Kingdom
| – | -$12K | -811 | Closed |
|
|
OC
33
Oppenheimer & Co
New York
| – | -$7K | -500 | Closed |
|
34
Wells Fargo
San Francisco,
California
| – | +$63 | +3 | +18% |
|
OTLK Hedge Fund Activity: Q4 2020 in Review
30 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2020, worth a combined $7.76M — up 178% from $2.79M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OTLK positions and 4 closed out — a net gain of 5 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.73M. The largest seller was Renaissance Technologies, cutting an estimated $54.4K.
- 30 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2020, up from 27 in Q3 2020.
- Funds reported $7.76M of Outlook Therapeutics stock for Q4 2020, up 178% quarter-over-quarter.
- 9 funds opened new Outlook Therapeutics positions in Q4 2020 and 4 closed out, a net change of +5 holders.
- The largest Outlook Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $1.73M added.
- The largest Outlook Therapeutics seller in Q4 2020 was Renaissance Technologies, an estimated $54.4K sold.
Based on aggregated 13F filings for Q4 2020.